Children's Cancer Therapy Development Institute, 12655 SW Beaverdam Rd West, Beaverton, OR, 97005, USA.
Xentech, Evry, France.
Sci Rep. 2021 Dec 2;11(1):23302. doi: 10.1038/s41598-021-02509-3.
Preclinical cancer research ranges from in vitro studies that are inexpensive and not necessarily reflective of the tumor microenvironment to mouse studies that are better models but prohibitively expensive at scale. Chorioallantoic membrane (CAM) assays utilizing Japanese quail (Coturnix japonica) are a cost-effective screening method to precede and minimize the scope of murine studies for anti-cancer efficacy and drug toxicity. To increase the throughput of CAM assays we have built and optimized an 11-day platform for processing up to 200 quail eggs per screening to evaluate drug efficacy and drug toxicity caused by a therapeutic. We demonstrate ex ovo concordance with murine in vivo studies, even when the in vitro and in vivo studies diverge, suggesting a role for this quail shell-free CAM xenograft assay in the validation of new anti-cancer agents.
临床前癌症研究范围从成本低廉且不一定能反映肿瘤微环境的体外研究，到更接近实际情况但成本极高的小鼠研究。利用日本鹌鹑（Coturnix japonica）进行的鸡胚尿囊膜（CAM）分析是一种经济有效的筛选方法，可以在进行小鼠研究之前对其进行筛选，并将其范围最小化，以评估抗癌疗效和药物毒性。为了提高 CAM 分析的通量，我们构建并优化了一个 11 天的平台，可在每次筛选中处理多达 200 个鹌鹑蛋，以评估治疗药物的疗效和毒性。我们证明了鸡胚尿囊膜异种移植物分析与小鼠体内研究的体外一致性，即使体外和体内研究存在分歧，这表明这种无壳鸡胚尿囊膜异种移植物分析在验证新的抗癌药物方面具有一定作用。
